442 805

Cited 1029 times in

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

DC Field Value Language
dc.contributor.author백순명-
dc.date.accessioned2018-03-26T16:56:53Z-
dc.date.available2018-03-26T16:56:53Z-
dc.date.issued2015-
dc.identifier.issn0028-4793-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/156991-
dc.description.abstractBACKGROUND: Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, a prospectively conducted study in a uniformly treated population provides the highest level of evidence supporting the clinical validity and usefulness of a biomarker. METHODS: We performed a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0 cm in the greatest dimension and intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features. A reverse-transcriptase-polymerase-chain-reaction assay of 21 genes was performed on the paraffin-embedded tumor tissue, and the results were used to calculate a score indicating the risk of breast-cancer recurrence; patients were assigned to receive endocrine therapy without chemotherapy if they had a recurrence score of 0 to 10, indicating a very low risk of recurrence (on a scale of 0 to 100, with higher scores indicating a greater risk of recurrence). RESULTS: Of the 10,253 eligible women enrolled, 1626 women (15.9%) who had a recurrence score of 0 to 10 were assigned to receive endocrine therapy alone without chemotherapy. At 5 years, in this patient population, the rate of invasive disease-free survival was 93.8% (95% confidence interval [CI], 92.4 to 94.9), the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI, 98.7 to 99.6), the rate of freedom from recurrence of breast cancer at a distant or local-regional site was 98.7% (95% CI, 97.9 to 99.2), and the rate of overall survival was 98.0% (95% CI, 97.1 to 98.6). CONCLUSIONS: Among patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.).-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMassachusetts Medical Society-
dc.relation.isPartOfNEW ENGLAND JOURNAL OF MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAge Factors-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Agents, Hormonal/therapeutic use*-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHBreast Neoplasms/drug therapy*-
dc.subject.MESHBreast Neoplasms/genetics*-
dc.subject.MESHBreast Neoplasms/surgery-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHFemale-
dc.subject.MESHGene Expression-
dc.subject.MESHGene Expression Profiling-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMastectomy-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHNeoplasm Grading-
dc.subject.MESHNeoplasm Recurrence, Local/epidemiology-
dc.subject.MESHNeoplasm Recurrence, Local/prevention & control*-
dc.subject.MESHProspective Studies-
dc.subject.MESHReceptor, ErbB-2-
dc.subject.MESHReceptors, Estrogen-
dc.subject.MESHReceptors, Progesterone-
dc.subject.MESHReverse Transcriptase Polymerase Chain Reaction-
dc.subject.MESHSurvival Analysis-
dc.titleProspective Validation of a 21-Gene Expression Assay in Breast Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Life Science-
dc.contributor.googleauthorJ.A. Sparano-
dc.contributor.googleauthorR.J. Gray-
dc.contributor.googleauthorD.F. Makower-
dc.contributor.googleauthorK.I. Pritchard-
dc.contributor.googleauthorK.S. Albain-
dc.contributor.googleauthorD.F. Hayes-
dc.contributor.googleauthorC.E. Geyer Jr.-
dc.contributor.googleauthorE.C. Dees-
dc.contributor.googleauthorE.A. Perez-
dc.contributor.googleauthorJ.A. Olson Jr.-
dc.contributor.googleauthorJ.A. Zujewski-
dc.contributor.googleauthorT. Lively-
dc.contributor.googleauthorS.S. Badve-
dc.contributor.googleauthorT.J. Saphner-
dc.contributor.googleauthorL.I. Wagner-
dc.contributor.googleauthorT.J. Whelan-
dc.contributor.googleauthorM.J. Ellis-
dc.contributor.googleauthorS. Paik-
dc.contributor.googleauthorW.C. Wood-
dc.contributor.googleauthorP. Ravdin-
dc.contributor.googleauthorM.M. Keane-
dc.contributor.googleauthorH.L. Gomez Moreno-
dc.contributor.googleauthorP.S. Reddy-
dc.contributor.googleauthorT.F. Goggins-
dc.contributor.googleauthorI.A. Mayer-
dc.contributor.googleauthorA.M. Brufsky-
dc.contributor.googleauthorD.L. Toppmeyer-
dc.contributor.googleauthorV.G. Kaklamani-
dc.contributor.googleauthorJ.N. Atkins-
dc.contributor.googleauthorJ.L. Berenberg-
dc.contributor.googleauthorG.W. Sledge-
dc.identifier.doi10.1056/NEJMoa1510764-
dc.contributor.localIdA01823-
dc.relation.journalcodeJ02371-
dc.identifier.eissn1533-4406-
dc.identifier.pmid26412349-
dc.contributor.alternativeNamePaik, Soon Myung-
dc.contributor.affiliatedAuthorPaik, Soon Myung-
dc.citation.volume373-
dc.citation.number21-
dc.citation.startPage2005-
dc.citation.endPage2014-
dc.identifier.bibliographicCitationNEW ENGLAND JOURNAL OF MEDICINE, Vol.373(21) : 2005-2014, 2015-
dc.identifier.rimsid41300-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.